Is INBX or IOVA more undervalued in 2026?

CirclFi compares Inhibrx Biosciences, Inc. (INBX) and Iovance Biotherapeutics, Inc. (IOVA) using 13 institutional-grade valuation models. INBX has a Quality of Company score of 5.3/10 while IOVA scores 5.1/10.

Which is a better buy — INBX or IOVA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do INBX and IOVA valuations compare?

INBX at $104.01 and IOVA at $4.10 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

INBX vs IOVA Valuation Comparison 2026 — Intrinsic Value Analysis

INBX

Biological Products, (No Diagnostic Substances)

Inhibrx Biosciences, Inc.

Quality

5.3

out of 10

Value Trap

SAFE

Price

$104.01

Last close

Models

8/13

Active

IOVA

Biological Products, (No Diagnostic Substances)

Iovance Biotherapeutics, Inc.

Quality

5.1

out of 10

Value Trap

SAFE

Price

$4.10

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	INBX Fair Value	INBX Upside	IOVA Fair Value	IOVA Upside
Bayesian DCF	Intrinsic	$29.90	-71.3%	$1.12	-72.7%
Earnings Power Value	Intrinsic	—	—	$0.72	-78.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.89	-97.2%	$1.69	-58.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for INBX vs IOVA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

INBX vs IOVA — Which Stock Is More Undervalued?

INBX scores higher with a 5.3/10 quality rating vs IOVA's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Inhibrx Biosciences, Inc. (INBX) and Iovance Biotherapeutics, Inc. (IOVA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

INBX currently trades at $104.01 with a QOC of 5.3/10, while IOVA trades at $4.10 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).